Ana Clara P. Azevedo‐Pouly

Researcher

UAMS

Last publication 2025 Last refreshed 2026-05-16

faculty

13 h-index 35 pubs 760 cited

Research Areas

Links

ORCID Lab Website

OverviewAI-generated summary

Ana Clara P. Azevedo‐Pouly's research focuses on understanding the molecular mechanisms underlying pancreatic cancer and immune cell function. Her work investigates the role of DNA-activated protein kinase catalytic subunit (DNA-PKcs) in regulating gene expression and stabilizing transcription factors such as Egr1, particularly in immune cells like T cells. She has also explored the potential of pharmacological interventions, including the development of novel DNA-PKcs inhibitors like DA-143, to modulate immune cell activity and cytotoxicity. Additionally, her research extends to studying the cellular processes involved in pancreatic acinar cell metaplasia and oncogenic transformation, examining key transcriptional effectors that influence these phenotypes. Azevedo‐Pouly has also investigated the cardiotoxic effects of doxorubicin in mice, exploring the involvement of the apelin-APJ pathway. Her collaborations include work with Randall R Rainwater, Brian Koss, Lauren Elizabeth Appell, and Melanie Barker at the University of Arkansas for Medical Sciences, with whom she has co-authored multiple publications.

Metrics

h-index: 13
Publications: 35
Citations: 760

Selected Publications

DNA-PKcs Controls the Cytotoxic T-Cell Response to Cancer and Transplant Allograft Through Regulating LAT-Dependent Signaling (2025)

DOI OpenAlex
DNA-PKcs governs LAT-dependent signaling in CD4 + and CD8 + T cells (2025)

DOI OpenAlex
The use of DNAPK inhibitors increases the efficacy of Lentiviral vectors and decreases off-target effects. (2024)

DOI OpenAlex
Discovery of the DNA-PKcs inhibitor DA-143 which exhibits enhanced solubility relative to NU7441 (2024)

2 citations DOI OpenAlex
Chemical inhibition of <scp>DNA‐PKcs</scp> impairs the activation and cytotoxicity of <scp>CD4</scp>+ helper and <scp>CD8</scp>+ effector T cells (2023)

6 citations DOI OpenAlex
DNA-PKcs is required for the activation and cytotoxicity of CD8+ effector T cells (2022)

DOI OpenAlex
Potential role of the apelin‐APJ pathway in sex‐related differential cardiotoxicity induced by doxorubicin in mice (2022)

4 citations DOI OpenAlex
Pharmacological inhibition and reversal of pancreatic acinar ductal metaplasia (2022)

22 citations DOI OpenAlex
Inhibition of DNA-PKcs impairs the activation and cytotoxicity of CD4 + helper and CD8 + effector T cells (2022)

DOI OpenAlex
DNA-PKcs kinase activity stabilizes the transcription factor Egr1 in activated immune cells (2021)

21 citations DOI OpenAlex
DNA-PKcs kinase activity stabilizes the transcription factor Egr1 in activated immune cells (2021)

1 citation DOI OpenAlex